GlassScriptPhysician profile
Varun Jain
NPI 1750764379
$1,272.09
in general payments reported to CMS, 2019-2025
16 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.34 · 2020: $84.21 · 2021: $103 · 2022: $426 · 2023: $179 · 2024: $260 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $242.99 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $192.65 | 2020-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $174.82 | 2022-2024 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.47 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $125.73 | 2021-2024 | Camzyos, Eliquis |
| Ceribell, INC. | $77.66 | 2025 | Pocket Eeg Device |
| Csl Behring | $73.66 | 2020-2023 | Kcentra |
| Novartis Pharmaceuticals Corporation | $45.00 | 2022-2023 | |
| Astellas Pharma US INC | $34.50 | 2024 | Cresemba |
| Ferring Pharmaceuticals INC. | $25.86 | 2023 | Rebyota |
| Atricure, INC. | $25.82 | 2025 | Atriclip Laa Exclusion System |
| Genzyme Corporation | $22.59 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.56 | 2025 | Austedo Xr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.43 | 2022 | |
| Merck Sharp & Dohme LLC | $18.34 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.